The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis
Terminated
Avid Radiopharmaceuticals
Phase 4
2017-01-01
The investigators postulate that F-18 florbetapir will show improved detection of cardiac
amyloidosis over conventional non-invasive imaging techniques, particularly in early disease.
The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis
Terminated
The Cleveland Clinic
Phase 4
2017-01-01
The investigators postulate that F-18 florbetapir will show improved detection of cardiac
amyloidosis over conventional non-invasive imaging techniques, particularly in early disease.
24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients
Active, not recruiting
Brigham and Women's Hospital
Phase 2
2019-02-28
Transthyretin is a protein produced in the liver that transports thyroid hormone and vitamin
A. A single substitution of an amino acid in the structure of TTR can result in a relatively
unstable protein, the breakdown products of which (predominantly monomers) aggregate
abnormally and produce proteinaceous deposits in nerves and the heart. These deposits are
known as amyloid and produce progressive nerve and heart damage. Amyloidosis due to a mutant
TTR is usually an autosomal dominant and hence is a familial condition. Wild-type TTR is also
capable of producing amyloid deposits which predominantly involves the heart (rather than the
nervous system) resulting in a progressive decrease in cardiac function with increasing signs
of heart failure. This study aims to determine whether subcutaneous injection of an antisense
oligonucleotide drug, known as inotersen, that has been specifically designed to reduce
production of the protein transthyretin by the liver, can slow or stop the progression of TTR
amyloid cardiomyopathy as compared to historical controls, using advanced echocardiography
and cardiac MRI. The study also aims to determine the tolerability and safety of this drug
when administered over a 24-month period to patients with TTR amyloid cardiomyopathy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
